Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Questions about clinical data aside, Imfinzi and tremelimumab could be filed for first-line lung cancer by the end of the year.
The Checkmate-9LA trial of Opdivo plus Yervoy yesterday read out positively for overall survival.
The remarkable speed of the company’s cystic fibrosis triplet approval will not distract attention from its price.
The amyloid-beta project is to be filed for Alzheimer’s, and Biogen’s market cap regains the $15bn it lost in March.
Zolgensma’s impressive early sales figures spur hopes that gene therapy could finally be coming of age.
Tucatinib yields a positive result in breast cancer, vindicating Seattle Genetics’ acquisition of its originator.
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.
EU rejection of Kiadis's stem cell transplant adjunct means that two of three players in this space have been knocked back.